MeSH term
Frequency | Condition_Probility | Cell Line, Tumor | 2 | 0.0 |
Humans | 60 | 0.0 |
Receptors, Somatostatin/metabolism | 2 | 11.0 |
Adult | 24 | 0.0 |
Aged | 19 | 0.0 |
Female | 27 | 0.0 |
*Gene Expression | 4 | 0.0 |
Male | 26 | 0.0 |
Middle Aged | 23 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 42 | 0.0 |
Animals | 22 | 0.0 |
COS Cells | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Receptors, Somatostatin/genetics/*metabolism | 5 | 38.0 |
Transfection | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Cell Line | 4 | 0.0 |
Gene Expression | 4 | 0.0 |
Molecular Sequence Data | 12 | 0.0 |
Tumor Cells, Cultured | 11 | 0.0 |
Aminoquinolines/pharmacology | 2 | 22.0 |
Dopamine Agonists/pharmacology | 2 | 11.0 |
Oligopeptides/pharmacology | 5 | 2.0 |
Piperazines/pharmacology | 5 | 4.0 |
Prolactin/antagonists & inhibitors/secretion | 2 | 66.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Human Growth Hormone/antagonists & inhibitors/*secretion | 2 | 66.0 |
Somatostatin/*analogs & derivatives/*pharmacology | 4 | 44.0 |
Aged, 80 and over | 5 | 0.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Indium Radioisotopes/diagnostic use | 2 | 11.0 |
Octreotide/therapeutic use | 2 | 15.0 |
Receptors, Somatostatin/*metabolism | 3 | 12.0 |
Cell Division | 3 | 0.0 |
Peptides, Cyclic/pharmacology | 3 | 8.0 |
Receptors, Somatostatin/*physiology | 2 | 33.0 |
Somatostatin/*analogs & derivatives/pharmacology | 3 | 25.0 |
Adolescent | 4 | 0.0 |
Phenotype | 2 | 0.0 |
Somatostatin/metabolism | 4 | 8.0 |
Comparative Study | 2 | 0.0 |
Prolactin/secretion | 2 | 1.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
In Vitro | 2 | 0.0 |
Radioligand Assay | 4 | 0.0 |
Receptors, Somatostatin/*biosynthesis | 2 | 28.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Base Sequence | 5 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Gene Library | 2 | 0.0 |
Receptors, Somatostatin/*genetics | 12 | 44.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Child | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Immunohistochemistry | 6 | 0.0 |
Receptors, Somatostatin/*genetics/*metabolism | 2 | 66.0 |
Receptors, Somatostatin/classification/*metabolism | 2 | 66.0 |
Research Support, U.S. Gov't, P.H.S. | 14 | 0.0 |
Acromegaly/*metabolism | 2 | 13.0 |
Cells, Cultured | 5 | 0.0 |
Hormones/pharmacology | 2 | 4.0 |
Octreotide/pharmacology | 5 | 20.0 |
Somatostatin/analogs & derivatives/pharmacology | 2 | 50.0 |
Pituitary Neoplasms/*metabolism | 2 | 5.0 |
Signal Transduction | 6 | 0.0 |
Lymphatic Metastasis/prevention & control | 2 | 66.0 |
Mice | 5 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Insulin/secretion | 2 | 3.0 |
Structure-Activity Relationship | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
RNA-Directed DNA Polymerase | 3 | 2.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Receptors, Somatostatin/classification/genetics/*physiology | 2 | 100.0 |
Somatostatin/*analogs & derivatives/*therapeutic use | 2 | 50.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Rats | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Human Growth Hormone/*secretion | 2 | 5.0 |
Pituitary Gland/drug effects/*metabolism | 2 | 33.0 |
Cell Survival/drug effects | 2 | 0.0 |
